Abstract
The soluble fragment of E-cadherin protein (S-ECD) is reported to be increased in the peripheral blood of cancer patients. In this study, we investigated the clinical significance of serum S-ECD in 81 patients with gastric cancer. The amount of serum S-ECD was significantly higher in the gastric cancer patients (4735 +/- 2310 ng ml(-1)) than in healthy volunteers (2515 +/- 744 ng ml(-1)). With the normal range cut-off at average +2 s.d., 67% patients showed abnormally high serum S-ECD levels. This frequency was significantly higher than that of other tumour markers, such as CEA (4.4%) or CA19-9 (13.3%). However, there was no significant correlation between the amount of S-ECD and clinicopathological factors. Serum S-ECD might be derived from cancer tissue, as removal of cancers by surgical treatment results in quick decline of the serum S-ECD and S-ECD can be detected by immunoblot in cancer tissues but not in normal epithelium. The serum S-ECD amount was compared with the E-cadherin expression in cancer tissues, which were classified into those showing preserved (+), partially reduced (+/-) or lost (-) expression. Interestingly, E-cadherin (+/-) tumours showed higher serum S-ECD levels than the other types, and a higher amount of S-ECD in the immunoblot analysis. Thus, the serum level of S-ECD may serve as an excellent tumour marker with high sensitivity. Furthermore, analysis of S-ECD in serum and cancer tissue can offer clues for elucidating the mechanism of reduction of E-cadherin expression in cancer cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gofuku, J., Shiozaki, H., Doki, Y. et al. Characterization of soluble E-cadherin as a disease marker in gastric cancer patients. Br J Cancer 78, 1095–1101 (1998). https://doi.org/10.1038/bjc.1998.634
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.634
This article is cited by
-
A novel FRET peptide assay reveals efficient Helicobacter pylori HtrA inhibition through zinc and copper binding
Scientific Reports (2020)
-
SEPROGADIC – serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy
Scientific Reports (2018)
-
Identification of E-cadherin signature motifs functioning as cleavage sites for Helicobacter pylori HtrA
Scientific Reports (2016)
-
Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma
Laboratory Investigation (2007)
-
Soluble cadherins as cancer biomarkers
Clinical & Experimental Metastasis (2007)